These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7456965)

  • 1. [Clinical study of fenofibrate in hyperlipoproteinemias].
    Ducobu J
    Acta Clin Belg; 1980; 35(3):148-54. PubMed ID: 7456965
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
    Sznajderman M
    Pol Arch Med Wewn; 1980 Jun; 63(6):543-9. PubMed ID: 7402954
    [No Abstract]   [Full Text] [Related]  

  • 3. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
    Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Cabrini E; Fasoli A
    Pharmacol Res Commun; 1984 Aug; 16(8):809-20. PubMed ID: 6593751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of phenofibrate on serum cholesterol and triglyceride concentration in patients with primary hyperlipoproteinemia].
    Cieślicka T; Paradowski S
    Pol Arch Med Wewn; 1983; 70(5-6):223-9. PubMed ID: 6677885
    [No Abstract]   [Full Text] [Related]  

  • 7. Fenofibrate in type IV and type V hyperlipoproteinemia.
    Seidehamel RJ
    Cardiology; 1989; 76 Suppl 1():23-8; discussion 29-32. PubMed ID: 2653622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias].
    Reiner Z; Salzer B; Kes P
    Acta Med Iugosl; 1988; 42(5):353-62. PubMed ID: 3245481
    [No Abstract]   [Full Text] [Related]  

  • 10. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
    Avogaro P; Bittolo Bon G; Belussi F; Pontoglio E; Cazzolato G
    Atherosclerosis; 1983 Apr; 47(1):95-100. PubMed ID: 6870993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
    Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
    Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of a hypolipemic drug (procetofene) on platelet functions and lipid composition in type II B hyperlipoproteinemia.
    Renaud S; Morazain R; Sauvanet JP; Dumont E; Drouin P
    Haemostasis; 1979; 8(2):82-95. PubMed ID: 499929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J; Vinzia C; Gómez JM; Morató J
    Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
    [No Abstract]   [Full Text] [Related]  

  • 20. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.
    Goldberg AC; Schonfeld G; Feldman EB; Ginsberg HN; Hunninghake DB; Insull W; Knopp RH; Kwiterovich PO; Mellies MJ; Pickering J
    Clin Ther; 1989; 11(1):69-83. PubMed ID: 2655907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.